Article
Hematology
Andrew F. Berdel, Raphael Koch, Joachim Gerss, Marcus Hentrich, Rudolf Peceny, Tobias Bartscht, Bjoern Steffen, Marina Bischoff, Karsten Spiekermann, Linus Angenendt, Jan-Henrik Mikesch, Tobias Kewitz, Trude Butterfass-Bahloul, Hubert Serve, Georg Lenz, Wolfgang E. Berdel, Utz Krug, Christoph Schliemann
Summary: This study investigated the safety and efficacy of adding nintedanib to low-dose cytarabine treatment in elderly patients with AML who were not eligible for intensive chemotherapy. The results showed that nintedanib did not demonstrate superior therapeutic activity compared to placebo in this population.
ANNALS OF HEMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Yvette N. Lamb
Summary: Nintedanib has been shown to be effective in slowing the progression of fibrotic interstitial lung diseases, particularly in patients with idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing ILDs, with manageable tolerability and no new safety concerns emerging from global pharmacovigilance data. It remains an important therapeutic option for patients with IPF and other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD.
Article
Pharmacology & Pharmacy
Tomislav Smoljo, Barbara Tomic, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Antonio Bedalov, Dora Visnjic
Summary: This study demonstrates that bone marrow stroma reduces differentiation of acute myeloid leukemia (AML) induced by low-dose cytarabine (LDAC). These findings provide insights into the limited occurrence of terminal differentiation observed in AML patients and suggest a potential explanation for this observation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Li Ye, Lingsu Gao, Qiansong Cheng, Feng Guo, Liang He, Tingting Yuan, Ming Zhu, Yuanfang Ma, Min Pan, Xiandeng Chu, Meiqi Ding, Guohui Yu
Summary: The study found that AML patients receiving single-intermediate dose cytarabine after reaching CR showed better relapse-free time and similar toxic effects compared to those receiving standard-dose cytarabine, indicating that ID cytarabine can improve the prognosis of AML patients.
Article
Oncology
Alexandre Bazinet, Faezeh Darbaniyan, Tapan M. Kadia, Sangeetha Venugopal, Rashmi Kanagal-Shamanna, Courtney D. DiNardo, Gautam Borthakur, Elias J. Jabbour, Naval G. Daver, Naveen Pemmaraju, Marina Y. Konopleva, Farhad Ravandi, Koji Sasaki, Kelly S. Chien, Danielle Hammond, Sherry A. Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo
Summary: CLAD/LDAC/HMA-based regimens are effective in a subset of patients with higher risk CMML and sAML arising from CMML who have not previously experienced HMA failure.
Article
Multidisciplinary Sciences
Nichole Owen, Irina G. Minko, Samantha A. Moellmer, Sydney K. Cammann, R. Stephen Lloyd, Amanda K. McCullough
Summary: Human clinical trials suggest that inhibition of enzymes in the DNA base excision repair (BER) pathway, such as PARP1 and APE1, can be useful in anticancer strategies when combined with certain DNA-damaging agents. Specifically, in acute myeloid leukemia (AML), AML cell lines deficient in OGG1 have enhanced sensitivity to cytarabine (Ara-C) treatment. This enhanced cytotoxicity is likely due to the insertion of Ara-C opposite unrepaired 8-oxo-dG in OGG1-deficient AML cells.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Oncology
Margaret T. Kasner, Molly B. Halloran, Jonathan Pan, Ellen K. Ritchie, Gerald J. Fetterly, Douglas Kramer, David G. Hangauer, James E. Thompson
Summary: This study evaluated the safety and activity of KX2-391 in elderly patients with AML. The results showed that KX2-391 had a certain improvement in patients' condition at certain doses, and its concentration in the bone marrow was similar to plasma concentrations. However, dose-limiting toxicities also occurred in some patients.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Bozena Katarzyna Budziszewska, Aleksander Salomon-Perzynski, Katarzyna Pruszczyk, Joanna Barankiewicz, Agnieszka Pluta, Grzegorz Helbig, Anna Janowska, Marta Kuydowicz, Lukasz Bolkun, Jaroslaw Piszcz, Elzbieta Patkowska, Marzena Watek, Piotr Malecki, Sylwia Kosciolek-Zgodka, Edyta Cichocka, Grzegorz Charlinski, Anna Irga-Staniukiewicz, Jan Maciej Zaucha, Agnieszka Piekarska, Tomasz Gromek, Marek Hus, Karol Wojcik, Malgorzata Razny, Mariola Sedzimirska, Bartosz Pula, Sebastian Giebel, Sebastian Grosicki, Agnieszka Wierzbowska, Ewa Lech-Maranda
Summary: The study evaluated a novel low-intensity regimen for elderly AML patients unfit for intensive chemotherapy, showing that LD-AC+cladribine led to positive outcomes in terms of objective response rate and overall survival, with predictable toxicity profile.
Article
Multidisciplinary Sciences
Rebecca Anderson, Lance D. Miller, Scott Isom, Jeff W. Chou, Kristin M. Pladna, Nathaniel J. Schramm, Leslie R. Ellis, Dianna S. Howard, Rupali R. Bhave, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell, Timothy S. Pardee
Summary: This study reports the results of a phase II study that combines devimistat with cytarabine and mitoxantrone in patients with relapsed or refractory AML. The study found that inhibition of mitochondrial fission or autophagy sensitizes AML cells to devimistat. Additionally, an age-related decline in mitochondrial quality and autophagy may be associated with response to devimistat.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Motoyasu Kato, Shinichi Sasaki, Wataru Mori, Makiko Kohmaru, Takashi Akimoto, Eri Hayakawa, Soichiro Soma, Yuta Arai, Naho Sakamoto Matsubara, Shun Nakazawa, Takuto Sueyasu, Haruki Hirakawa, Hiroaki Motomura, Issei Sumiyoshi, Yusuke Ochi, Junko Watanabe, Kazuaki Hoshi, Kotaro Kadoya, Hiroaki Ihara, Jia Hou, Shinsaku Togo, Kazuhisa Takahashi
Summary: This study aimed to investigate the efficacy and safety of nintedanib administration after AE-ILD development. The results showed that patients who received nintedanib had longer survival time and delayed onset of subsequent AE-ILD. However, nintedanib administration may also lead to adverse gastrointestinal effects and liver dysfunction.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Hui-Jen Tsai, Hui-Hua Hsiao, Ya-Ting Hsu, Yi-Chang Liu, Hsiao-Wen Kao, Ta-Chih Liu, Shih-Feng Cho, Xiaoxing Feng, Amanda Johnston, John S. Bomalaski, Ming-Chung Kuo, Tsai-Yun Chen
Summary: The combination therapy of ADI-PEG20 and low-dose cytarabine in AML patients showed promising efficacy with good tolerability, leading to an encouraging overall response rate. Further studies on this combination are warranted.
Article
Oncology
Jun-Feng Zhu, Hai-Ping Dai, Qian-Qian Zhang, Jia Yin, Zheng Li, Qin-Ya Cui, Xiao-Peng Tian, Si-Ning Liu, Zheng-Ming Jin, Xia-Ming Zhu, De-Pei Wu, Xiao-Wen Tang
Summary: In this retrospective study, the decitabine combined with HAAG regimen demonstrated effective and well-tolerated induction therapy in patients with newly diagnosed acute myeloid leukemia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Madeleine A. Ochs, Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Dale L. Bixby, Kristen M. Pettit, Lydia L. Benitez
Summary: There were no significant differences in safety or efficacy outcomes for obese versus non-obese patients who received HIDAC consolidation, suggesting that weight does not impact the dosage of this therapy.
Review
Oncology
Valerie Relias, Ali McBride, Matthew J. Newman, Shilpa Paul, Seyyedeh Saneeymehri, Genique Stanislaus, Jennifer Tobin, Caroline J. Hoang, Joanne C. Ryan, Ilene Galinsky
Summary: Acute myeloid leukemia (AML) primarily affects older adults and treatment options for this group are limited. Glasdegib, when used in combination with low-dose cytarabine (LDAC), has shown superior overall survival compared to LDAC alone. The individualized delivery of treatment plans may help patients stay on therapy longer and potentially achieve greater benefits.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2021)
Article
Hematology
Colin A. Vale, Pamela C. Egan, Randall Ingham, Dimitrios Farmakiotis, John L. Reagan
Summary: For AML patients receiving cytarabine consolidation treatment, antibacterial prophylaxis did not decrease rates of febrile neutropenia, hospitalization, or bacteremia, and was associated with higher risk of infection from drug-resistant bacteria in cycle 1.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Daniela V. Wenge, Klaus Wethmar, Corinna A. Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brueggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Summary: This retrospective study evaluated the treatment outcomes of 93 elderly patients with acute lymphoblastic leukemia who received intensive chemotherapy. The study identified age and performance status as risk factors for poor outcomes, while intensity of treatment and disease characteristics did not significantly affect overall survival. The results suggest that intensive treatment of elderly ALL patients is feasible but associated with significant toxicity.
Article
Cell & Tissue Engineering
Ming Ni, Lei Wang, Yuntian Ding, Wenjie Gong, Sanmei Wang, Brigitte Neuber, Maria-Luisa Schubert, Tim Sauer, Angela Huckelhoven-Krauss, Thomas Luft, Ute Hegenbart, Stefan Schonland, Volker Eckstein, Jishi Wang, William Kruger, Carsten Muller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt
Summary: Extracorporeal photopheresis (ECP), a personalized cellular immunotherapy, shows promising results in the treatment of steroid-refractory/-resistant graft-versus-host disease (SR-GvHD) by modulating different subsets of T cells and inducing immune tolerance.
Article
Oncology
Sebastian Stasik, Michael Kramer, Sven Zukunft, Christoph Rollig, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Carsten Muller-Tidow, Kerstin Schafer-Eckart, Martin Kaufmann, Stefan Krause, Tim Sauer, Mathias Hanel, Andreas Neubauer, Gerhard Ehninger, Martin Bornhauser, Johannes Schetelig, Jan M. Middeke, Christian Thiede
Summary: Non-ITD mutations in FLT3 JMD region are rare but associated with other mutations, particularly KMT2A-PTD. However, FLT3 non-ITD mutations are not an independent prognostic factor according to multivariable analysis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Andrew F. Berdel, Leo Ruhnke, Linus Angenendt, Martin Wermke, Christoph Roellig, Jan-Henrik Mikesch, Annika Scheller, Teresa Hemmerle, Mattia Matasci, Klaus Wethmar, Torsten Kessler, Mirjam Gerwing, Daniel Hescheler, Michael Schaefers, Wolfgang Hartmann, Bianca Altvater, Claudia Rossig, Martin Bornhaeuser, Georg Lenz, Matthias Stelljes, Bjoern Rueter, Dario Neri, Wolfgang E. Berdel, Christoph Schliemann
Summary: This study explores a novel treatment strategy that enhances the immune response of NK cells against leukemia cells by combining an antibody-cytokine fusion and an anti-CD33 antibody. Preliminary results show that this combination therapy has promising biological and clinical activity in the treatment of posttransplant AML relapse.
Article
Hematology
Maike Janssen, Christina Schmidt, Peter-Martin Bruch, Maximilian F. Blank, Christian Rohde, Alexander Waclawiczek, Daniel Heid, Simon Renders, Stefanie Goellner, Lisa Vierbaum, Birgit Besenbeck, Sophie A. Herbst, Mareike Knoll, Carolin Kolb, Adriana Przybylla, Katharina Weidenauer, Anne Kathrin Ludwig, Margarete Fabre, Muxin Gu, Richard F. Schlenk, Friedrich Stoelzel, Martin Bornhaeuser, Christoph Roellig, Uwe Platzbecker, Claudia Baldus, Hubert Serve, Tim Sauer, Simon Raffel, Caroline Pabst, George Vassiliou, Binje Vick, Irmela Jeremias, Andreas Trumpp, Jeroen Krijgsveld, Carsten Mueller-Tidow, Sascha Dietrich
Summary: This study found that gilteritinib had the best synergy with venetoclax in FLT3 wild-type AML through high-throughput drug screening. The combination of gilteritinib and venetoclax increased apoptosis, reduced cell viability, and showed activity in venetoclax-azacitidine-resistant cell lines and primary patient samples.
Review
Oncology
Linus Angenendt, Jan-Henrik Mikesch, Christoph Schliemann
Summary: The development of antibody-based therapeutics for patients with acute myeloid leukemia has been challenging due to the shared expression of antigens on leukemic blasts and hematopoietic stem and progenitor cells. However, recent years have seen the approval of the first antibody-drug conjugate for AML treatment, and promising results from other antibody-based therapeutics in clinical trials.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Maher Hanoun, Leo Ruhnke, Michael Kramer, Christine Hanoun, Kerstin Schaefer-Eckart, Bjoern Steffen, Tim Sauer, Stefan W. Krause, Christoph Schliemann, Jan-Henrik Mikesch, Martin Kaufmann, Mathias Haenel, Edgar Jost, Tim H. Bruemmendorf, Lars Fransecky, Sabrina Kraus, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Johannes Kullmer, Ruth Seggewiss-Bernhard, Martin Goerner, Gerhard Held, Ulrich Kaiser, Sebastian Scholl, Andreas Hochhaus, H. Christian Reinhardt, Uwe Platzbecker, Claudia D. Baldus, Carsten Mueller-Tidow, Martin Bornhaeuser, Hubert Serve, Christoph Roellig
Summary: This retrospective analysis of real-world data from the SAL-AML registry suggests that there is no significant benefit of high-dose cytarabine compared to intermediate dosages in consolidation therapy for AML patients under 65 years of age.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Fengbiao Zhou, Nesrine Aroua, Yi Liu, Christian Rohde, Jingdong Cheng, Anna-Katharina Wirth, Daria Fijalkowska, Stefanie Goellner, Michelle Lotze, Haiyang Yun, Xiaobing Yu, Caroline Pabst, Tim Sauer, Thomas Oellerich, Hubert Serve, Christoph Roellig, Martin Bornhaeuser, Christian Thiede, Claudia Baldus, Michaela Frye, Simon Raffel, Jeroen Krijgsveld, Irmela Jeremias, Roland Beckmann, Andreas Trumpp, Carsten Mueller-Tidow
Summary: The dynamic 2'-O-methylation of ribosomal RNA regulates leukemia stem cell activity in acute myeloid leukemia. The methylation pattern is associated with AML development stage and stem cell gene expression. Enhanced 2'-O-methylation redirects ribosome translation and controls AML stem cell self-renewal.
Article
Hematology
Andrew F. Berdel, Raphael Koch, Joachim Gerss, Marcus Hentrich, Rudolf Peceny, Tobias Bartscht, Bjoern Steffen, Marina Bischoff, Karsten Spiekermann, Linus Angenendt, Jan-Henrik Mikesch, Tobias Kewitz, Trude Butterfass-Bahloul, Hubert Serve, Georg Lenz, Wolfgang E. Berdel, Utz Krug, Christoph Schliemann
Summary: This study investigated the safety and efficacy of adding nintedanib to low-dose cytarabine treatment in elderly patients with AML who were not eligible for intensive chemotherapy. The results showed that nintedanib did not demonstrate superior therapeutic activity compared to placebo in this population.
ANNALS OF HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Matthias Stelljes, Nael Alakel, Ralph Waesch, Sebastian Scholl, Kathrin Nachtkamp, Andreas Rank, Mathias Haenel, Bernd Spriewald, Maher Hanoun, Sonja Martin, Katjana Schwab, Julian Knaden, Lena Reiser, Julia Marx, Klaus Wethmar, Tim Sauer, Wolfgang E. Berdel, Georg Lenz, Monika Brueggemann, Simon Raffel, Nicola Goekbuget
Meeting Abstract
Hematology
Julia M. Unglaub, Richard F. Schlenk, Maher Hanoun, H. Christian Reinhardt, Jan Moritz Middeke, Kerstin Schaefer-Eckart, Bjoern Steffen, Stefan W. Krause, Christoph Schliemann, Martin Kaufmann, Mathias Haenel, Edgar Jost, Martina Crysandt, Lars Fransecky, Hermann Einsele, Sabrina Kraus, Dirk Niemann, Andreas Neubauer, Ruth Seggewiss-Bernhardt, Sebastian Scholl, Stefan Klein, Christoph Schmid, Markus Schaich, Uwe Platzbecker, Claudia D. Baldus, Martin Bornhaeuser, Hubert Serve, Christoph Roellig, Michael Kramer, Elena Katelari, Maike Janssen, Caroline Pabst, Thomas Luft, Peter Dreger, Carsten Mueller-Tidow, Tim Sauer
Article
Oncology
Jan-Niklas Eckardt, Sebastian Stasik, Christoph Rollig, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Bruemmendorf, Ralph Naumann, Bjoern Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schaefer-Eckart, Christoph Schliemann, Stefan W. Krause, Regina Herbst, Mathias Haenel, Maher Hanoun, Ulrich Kaiser, Martin Kaufmann, Zdenek Racil, Jiri Mayer, Tiago Cerqueira, Frank Kroschinsky, Wolfgang E. Berdel, Hubert Serve, Carsten Mueller-Tidow, Uwe Platzbecker, Claudia D. Baldus, Johannes Schetelig, Timo Siepmann, Martin Bornhaeuser, Jan Moritz Middeke, Christian Thiede
Summary: Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reported in various cancers, including AML. Mutations of its STAG2 subunit were found to be associated with unfavorable risk in AML patients, but limited evidence and conflicting observations exist regarding their clinical outcomes. We analyzed data from 1615 AML patients and identified distinct co-mutational patterns for STAG2 mutations. We also found mutual exclusivity of genetic alterations in individual cohesin subunits, suggesting potential therapeutic strategies for cohesin mutated AML.
BLOOD CANCER JOURNAL
(2023)
Meeting Abstract
Oncology
Stephanie Fetzko, Ishwar Navin, Matthew Dysthe, Tim Sauer, Cliona Rooney, Robin Parihar
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Meeting Abstract
Oncology
A. F. Berdel, R. Koch, J. Gerss, M. Hentrich, R. Peceny, T. Bartscht, B. Steffen, M. Bischoff, K. Spiekermann, L. Angenendt, J. -H. Mikesch, T. Kewitz, T. Butterfass-Bahloul, H. Serve, G. Lenz, W. E. Berdel, U. Krug, C. Schliemann
ONCOLOGY RESEARCH AND TREATMENT
(2022)